With an outcomes-based design 1 and reduced procedural complexity 2, it’s designed to meet previously unmet surgical needs in hip fracture treatment. The TFN-ADVANCED Nailing System is a part of the Advanced Nailing System from DePuy Synthes and has features that allow surgeons to address proximal femur fractures. The system includes:

Feb 7, 2024 · Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary endpoints including PASIa 100 and IGAb 0 responses of 40.5 percent and 45.2 percent, respectively.

2 days ago · Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

Nov 19, 2024 · JNJ-2113's potential as a first-in-class oral therapy for psoriasis is supported by its efficacy, tolerability, and IL-23 receptor targeting. Future studies will evaluate JNJ-2113 in ulcerative colitis and psoriatic arthritis, with results anticipated in 2025.

Mar 9, 2024 · JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting.

Mar 8, 2025 · Johnson Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO) seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab.

Jul 4, 2023 · JNJ-2113 is a novel oral IL-23R antagonist peptide that binds with high affinity to the IL-23R and has properties that allow it to be absorbed with oral dosing. 2,3 The IL-23/IL-23R signaling pathway plays a critical role in the pathogenesis of immune-mediated inflammatory diseases, including PsO. 4,5 JNJ-2113 selectively and potently blocks IL-...

Find the latest Johnson & Johnson (JNJ) stock quote, history, news and other vital information to help you with your stock trading and investing.

Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. Information about our Innovative Medicine patent portfolio.

TFN-ADVANCEDTM PROXIMAL FEMORAL NAILI. r 2022 Overview Since its introduction in 2015, the TFN-ADVANCEDTM Proximal Femoral Nailing System (TFNA) has sold over 700,000 nails in 44 countries.1 To date, published data on the TFNA System has included clinical studies, case reports, and other biomechanical or ana.